DUPO, ILLINOIS / RankWire.AI / – Sterling Pharmaceutical Services has issued a recall for nearly 748,000 eye-care products nationwide over sterility assurance issues. The recall notably affects over 500,000 packages branded by Walgreens. The company commenced the recall on August 20 following findings from a federal inspection. Subsequently, the U.S. Food and Drug Administration classified this action as a Class II recall, indicating that the affected products might cause temporary or medically reversible health effects, with the likelihood of serious consequences remaining low.

Federal records reveal that Walgreens products constitute the largest segment of the recall, totaling 500,714 packages. This figure includes 301,114 bottles of Walgreens Lubricant Eye Drops and 199,600 twin packs. These products contain carboxymethylcellulose sodium 0.5%, which alleviates burning and irritation associated with dry eyes. Distribution across the United States was managed by Walgreen Co., with several affected lots showing expiration dates extending into 2027.
The recall extends beyond Walgreens products to include items marketed under various brands and distributors. For instance, AvKare listings account for 120,241 twin packs of lubricant eye drops. Reliable-1 Laboratories products include 47,616 units of Lubricating Tears and 11,083 units of sodium chloride ophthalmic solution. Additional affected products are associated with Cameron Pharmaceuticals, TRP, and Major Pharmaceuticals. Federal records show a total of 747,844 units across nine product listings linked to Sterling Pharmaceutical Services.
Concerns about sterility prompted federal inspection
AvKare indicated that Sterling initiated the recall following a request from the FDA, after observations made during a recent inspection. These findings involved manufacturing controls and aseptic processing, which are critical to ensuring sterile drug products are not contaminated. AvKare clarified that Sterling had not identified confirmed failures in sterility or evidence of product contamination. The company described the recall as a precautionary measure because the inspection findings impacted sterility assurance. Customers were also advised to discontinue use of the affected products.
Sterility controls are especially significant for ophthalmic medicines due to their direct application to the eyes. The FDA explicitly states that the recall was prompted by a lack of sterility assurance. Federal records provide detailed lot numbers and expiration dates for each affected item. The scope of the recall covers Walgreens, AvKare, Reliable-1 Laboratories, Cameron Pharmaceuticals, TRP, and Major Pharmaceuticals products, all traced back to Sterling’s manufacturing facility in Dupo, Illinois.
Walgreens products constitute the majority of the recalled units
Approximately two-thirds of the packages involved in the recall are Walgreens lubricant eye drops. The affected single-bottle lots have expiration dates ranging from September 2026 to June 2027, while twin-pack lots span from September 2026 through July 2027. Federal enforcement records identify Sterling Pharmaceutical Services as the entity responsible for the recall, with distribution across the nation. The FDA assigned the event number 99712 to this recall as part of its official enforcement documentation.
This 2026 recall follows previous federal scrutiny of Sterling’s Illinois facility, although it remains a separate regulatory action. In September 2022, the FDA issued Sterling a warning letter after inspecting the plant earlier that year. The letter highlighted deficiencies in manufacturing practices related to sterile ophthalmic products, contamination investigations, and aseptic processing controls. The current recall concerns sterility assurance following a more recent inspection. According to AvKare’s statement, no confirmed contamination or sterility failures have been identified to date.
